Diflomotecan

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDiflomotecan
Drug Alias Name二氟替康diflomotecanumR-1536BN-80915
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIpsen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIpsen
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A